278 related articles for article (PubMed ID: 1691134)
41. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
Link H; Freund M; Diedrich H; Wilke H; Austein J; Henke M; Wandt H; Fackler-Schwalbe E; Schlimok G; Hoffmann R
Haematol Blood Transfus; 1990; 33():322-5. PubMed ID: 2182426
[TBL] [Abstract][Full Text] [Related]
42. Phase II-trial of double-consolidation following intensive induction treatment for improvement of survival in elderly patients with acute myeloid leukemia.
Jehn U
Leuk Lymphoma; 1994 Feb; 12(5-6):435-40. PubMed ID: 8180607
[TBL] [Abstract][Full Text] [Related]
43. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
44. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
45. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
46. Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.
Witteveen EO; Verdonck LF; Nieuwenhuis HK; Dekker AW
Haematol Blood Transfus; 1990; 33():309-13. PubMed ID: 2323635
[No Abstract] [Full Text] [Related]
47. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
48. Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Freund M; Diedrich H; Ganser A; Gramatzki M; Heil G; Heyll A; Henke M; Hiddemann W; Haas R; Kuse R
Cancer; 1992 Feb; 69(3):709-16. PubMed ID: 1730121
[TBL] [Abstract][Full Text] [Related]
49. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
50. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
[TBL] [Abstract][Full Text] [Related]
51. The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia. Australian Leukemia Study Group.
Bishop JF; Matthews JP; Young G; Szer J; Joshua DE; Dodds A; Laidlaw CR; Cobcroft R; Herrman R; Ma D
Leuk Lymphoma; 1994 Sep; 15(1-2):79-84. PubMed ID: 7858505
[TBL] [Abstract][Full Text] [Related]
52. High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia.
Lie SO; Berglund G; Gustafsson G; Jonmundsson G; Siimes M; Yssing M
Haematol Blood Transfus; 1990; 33():215-21. PubMed ID: 2138994
[No Abstract] [Full Text] [Related]
53. Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Jehn U; Knüppel W; Wilmanns W
Onkologie; 1988 Feb; 11(1):13-7. PubMed ID: 3283620
[TBL] [Abstract][Full Text] [Related]
54. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
De Witte T; Suciu S; Selleslag D; Labar B; Roozendaal K; Zittoun R; Ribeiro M; Kurstjens R; Hayat M; Dardenne M; Solbu G; Muus P
Ann Hematol; 1996 Mar; 72(3):119-24. PubMed ID: 8766252
[TBL] [Abstract][Full Text] [Related]
55. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
Visani G; Petti MC; Cenacchi A; Manfroi S; Tosi P; Spadea A; Latagliata R; Amadori S; Mandelli F; Tura S
Leuk Lymphoma; 1995 Nov; 19(5-6):447-51. PubMed ID: 8590845
[TBL] [Abstract][Full Text] [Related]
56. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
57. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Cuttner J; Holland JF
Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
59. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
60. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
Pignon B; Witz F; Desablens B; Leprise PY; Francois S; Linassier C; Berthou C; Caillot D; Lioure B; Cahn JY; Casassus P; Sadoun A; Audhuy B; Guyotat D; Briere J; Vilque JP; Baranger L; Polin V; Berthaud P; Hurteloup P; Herve P; Harousseau JL
Br J Haematol; 1996 Aug; 94(2):333-41. PubMed ID: 8759894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
